Siphene

Siphene may be available in the countries listed below.

Ingredient matches for Siphene

Clomifene

Clomifene citrate (a derivative of Clomifene) is reported as an ingredient of Siphene in the following countries:

• India

International Drug Name Search

Telavancin Hydrochloride

Telavancin Hydrochloride may be available in the countries listed below.

Ingredient matches for Telavancin Hydrochloride

Telavancin

Telavancin Hydrochloride (USAN) is known as Telavancin in the US.

International Drug Name Search

Glossary

USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Uroxatral

Uroxatral is a brand name of alfuzosin, approved by the FDA in the following formulation(s):

UROXATRAL (alfuzosin hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: June 12, 2003
  
  Strength(s): 10MG ^[RLD][AB]

Has a generic version of Uroxatral been approved?

A generic version of Uroxatral has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Uroxatral and have been approved by the FDA:

alfuzosin hydrochloride tablet, extended release; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: INVAGEN PHARMS
  
  Approval date: January 17, 2012
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: TORRENT PHARMS
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uroxatral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Alfuzosine compositions and use
  Patent 4,661,491
  Issued: April 28, 1987
  Inventor(s): Regnier; Francois
  Assignee(s): Synthelabo
  A method for treating humans or non-human animals for dysuria comprising administering an effective non-toxic amount of alfuzosine or a pharmaceutically acceptable salt thereof to a human or non-human animal suffering dysuria.
  
  Patent expiration dates:
  
  
  • July 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Tablet with controlled release of alfuzosine chlorhydrate
  Patent 6,149,940
  Issued: November 21, 2000
  Inventor(s): Maggi; Lauretta & Conte; Ubaldo & Grenier; Pascal & Vergnault; Guy & Dufour; Alain & Jarreau; Fran.cedilla.ois Xavier & Rauch-Desanti; Clemence
  Assignee(s): Synthelabo
  Jagotec AB
  Pharmaceutical tablet which consists of: a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, and b) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.
  
  Patent expiration dates:
  
  
  • August 22, 2017
    
  
  
  
  • February 22, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2013 - LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
  
  
  • June 15, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Uroxatral Consumer Information (Drugs.com)
• Uroxatral Consumer Information (Wolters Kluwer)
• Uroxatral Consumer Information (Cerner Multum)
• Uroxatral Advanced Consumer Information (Micromedex)
• Uroxatral AHFS DI Monographs (ASHP)
• Alfuzosin Consumer Information (Wolters Kluwer)
• Alfuzosin Consumer Information (Cerner Multum)
• Alfuzosin Advanced Consumer Information (Micromedex)
• Alfuzosin Hydrochloride AHFS DI Monographs (ASHP)

Zidicef

Zidicef may be available in the countries listed below.

Ingredient matches for Zidicef

Ceftazidime

Ceftazidime is reported as an ingredient of Zidicef in the following countries:

• Bangladesh

International Drug Name Search

Diazepam Alter

Diazepam Alter may be available in the countries listed below.

Ingredient matches for Diazepam Alter

Diazepam

Diazepam is reported as an ingredient of Diazepam Alter in the following countries:

• Italy

International Drug Name Search

Droxia

In the US, Droxia (hydroxyurea systemic) is a member of the drug class antimetabolites and is used to treat Anemia - Sickle Cell, Chronic Myelogenous Leukemia, Polycythemia Vera and Solid Tumors.

US matches:

• Droxia

Ingredient matches for Droxia

Hydroxycarbamide

Hydroxycarbamide is reported as an ingredient of Droxia in the following countries:

• United States

International Drug Name Search

Siozwo Nasengel

Siozwo Nasengel may be available in the countries listed below.

Ingredient matches for Siozwo Nasengel

Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Siozwo Nasengel in the following countries:

• Germany

International Drug Name Search

Duragesic-75

See also: Generic Duragesic-100, Generic Duragesic-12, Generic Duragesic-25, Generic Duragesic-50

Duragesic-75 is a brand name of fentanyl, approved by the FDA in the following formulation(s):

DURAGESIC-75 (fentanyl - film, extended release; transdermal)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 7, 1990
  
  Strength(s): 75MCG/HR ^[AB]

Has a generic version of Duragesic-75 been approved?

Yes. The following products are equivalent to Duragesic-75:

FENTANYL-75 (fentanyl film, extended release; transdermal)

• 
  Manufacturer: ACTAVIS
  
  Approval date: August 20, 2007
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: LAVIPHARM LABS
  
  Approval date: August 4, 2006
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: February 9, 2011
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: MYLAN TECHNOLOGIES
  
  Approval date: January 28, 2005
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: NOVEN
  
  Approval date: October 16, 2009
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: October 20, 2008
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 20, 2007
  
  Strength(s): 75MCG/HR ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duragesic-75. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Duragesic-75.

See also...

• Duragesic-75 skin patch Consumer Information (Cerner Multum)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)